Corinne Epperly
Directeur/Membre du Conseil chez IN8BIO, INC.
Fortune : 85 246 $ au 30/04/2024
Postes actifs de Corinne Epperly
Sociétés | Poste | Début | Fin |
---|---|---|---|
IN8BIO, INC. | Directeur/Membre du Conseil | 07/12/2023 | - |
Independent Dir/Board Member | 07/12/2023 | - |
Historique de carrière de Corinne Epperly
Anciens postes connus de Corinne Epperly
Sociétés | Poste | Début | Fin |
---|---|---|---|
CARGO THERAPEUTICS, INC. | Directeur des opérations | 01/05/2021 | 01/12/2023 |
AVEO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 06/01/2021 | 19/01/2023 |
Independent Dir/Board Member | 06/01/2021 | 19/01/2023 | |
IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2019 | 01/01/2020 |
NOTABLE LABS, LTD. | Directeur des opérations | 01/01/2017 | 01/01/2018 |
Goldman Sachs International
Goldman Sachs International Investment Banks/BrokersFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Analyst-Equity | 14/04/2010 | 01/10/2010 |
Formation de Corinne Epperly
The University of North Carolina at Charlotte | Doctorate Degree |
University of Virginia | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Israël | 2 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Chief Operating Officer | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
CARGO THERAPEUTICS, INC. | Health Technology |
IN8BIO, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Goldman Sachs International
Goldman Sachs International Investment Banks/BrokersFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Finance |
- Bourse
- Insiders
- Corinne Epperly
- Expérience